Table 1.
Reference | Year | Region | Cancer type | Genotype methods | Sample size (case/control) | Source of control | DNA sample | Genotype—case | Genotype—control | HWE | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IL-8 −251 A/T | AA | AT | TT | AA | AT | TT | ||||||||
Shimizu et al48 | 2008 | Asian | Oral cancer | PCR-FRET | 69/91 | Population-based | Tissue | 8 | 30 | 31 | 8 | 45 | 38 | YES |
Campa et al49,a | 2007 | European | Oral cancer | TaqMan | 153/725 | Population-based | Blood | 41 | 72 | 40 | 158 | 370 | 197 | YES |
Campa et al49,b | 2007 | European | Pharynx cancer | TaqMan | 107/725 | Population-based | Blood | 31 | 50 | 26 | 158 | 370 | 197 | YES |
Campa et al49,c | 2007 | European | Laryngeal cancer | TaqMan | 313/725 | Population-based | Blood | 75 | 141 | 97 | 158 | 370 | 197 | YES |
Campa et al49,d | 2007 | European | Esophageal cancer | TaqMan | 171/822 | Population-based | Blood | 35 | 93 | 43 | 173 | 429 | 220 | YES |
Ben Nasr50 | 2007 | African | Nasopharyngeal cancer | AS-PCR | 160/169 | Population-based | Blood | 37 | 74 | 49 | 23 | 71 | 75 | YES |
Kietthubthew51 | 2010 | Asian | Oral cancer | Taq-Man | 63/99 | Population-based | Blood | 10 | 21 | 32 | 16 | 49 | 34 | YES |
Zhang | 2008 | Asian | Esophageal cancer | PCR-RFLP | 320/404 | Population-based | Blood | 50 | 175 | 95 | 74 | 200 | 130 | YES |
Liu53 | 2012 | Asian | Oral cancer | PCR-RFLP | 270/350 | Population-based | Blood | 42 | 131 | 97 | 66 | 164 | 120 | YES |
Wei54 | 2007 | Asian | Nasopharyngeal cancer | PCR-RFLP | 280/290 | Population-based | Blood | 54 | 137 | 89 | 42 | 122 | 126 | YES |
Tai55 | 2007 | Asian | Nasopharyngeal cancer | PCR-RFLP | 105/109 | Population-based | Blood | 11 | 52 | 42 | 17 | 53 | 39 | YES |
Liu67 | 2011 | Asian | Esophageal cancer | PCR-HRM | 351/384 | Hospital-based | Blood | 19 | 192 | 140 | 42 | 174 | 168 | YES |
Hu68 | 2012 | Asian | Oral cancer | PCR-HRM | 142/30 | Hospital-based | Tissue | 21 | 67 | 54 | 5 | 14 | 11 | YES |
Kiliç56 | 2016 | European | Thyroid cancer | PCR-RFLP | 101/109 | Population-based | Blood | 7 | 41 | 53 | 10 | 50 | 49 | YES |
A. Savage57 | 2004 | Asian | Esophageal cancer | Single base extension | 129/429 | Population-based | Blood | 26 | 55 | 48 | 75 | 207 | 147 | YES |
IL-18 −137 G/C | GG | GC | CC | GG | GC | CC | ||||||||
Abdolahi58 | 2015 | Asian | Thyroid cancer | PCR-RFLP | 105/148 | Population-based | Blood | 59 | 33 | 6 | 85 | 56 | 7 | YES |
Babar59 | 2011 | European | Esophageal cancer | TaqMan | 193/1082 | Population-based | Blood | 105 | 74 | 14 | 582 | 414 | 86 | YES |
Farhat60 | 2008 | African | Nasopharyngeal cancer | PCR-RFLP | 163/164 | Population-based | Blood | 75 | 73 | 15 | 83 | 68 | 13 | YES |
Asefi61 | 2008 | Asian | HNSCC | AS-PCR | 111/212 | Hospital-based | Blood | 65 | 37 | 9 | 116 | 79 | 17 | YES |
Tsai62 | 2013 | Asian | Oral cancer | TaqMan | 567/559 | Population-based | Blood | 437 | 122 | 8 | 476 | 78 | 5 | YES |
Pratesi63 | 2005 | European | Nasopharyngeal cancer | AS-PCR | 89/130 | Population-based | Blood | 43 | 39 | 7 | 72 | 53 | 5 | YES |
Nong64 | 2009 | Asian | Nasopharyngeal cancer | PCR-RFLP | 250/270 | Population-based | Blood | 140 | 88 | 22 | 189 | 70 | 11 | YES |
Wei65 | 2007 | Asian | Esophageal cancer | AS-PCR | 235/250 | Hospital-based | Blood | 127 | 91 | 17 | 176 | 66 | 8 | YES |
Pan69 | 2013 | Asian | Nasopharyngeal cancer | PCR-RFLP | 190/200 | Hospital-based | Blood | 102 | 74 | 14 | 139 | 52 | 9 | YES |
Chung66 | 2015 | Asian | Thyroid cancer | Sequencing | 94/260 | Hospital-based | Blood | 70 | 18 | 6 | 187 | 70 | 3 | YES |
Note: Superscripted a, b, c and d are parts of one study by Campa et al.49
Abbreviations: HWE, Hardy Weinberg equilibrium; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; AS-PCR, alleles specific polymerase chain reaction; HNSCC, head and neck squamous cell carcinoma; PCR-HRM, polymerase chain reaction-high resolution melt; PCR-FRET, polymerase chain reaction-fluorescence resonance energy transfer.